Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1642 1644 1645 1658
This examiner grants 63% of resolved cases
James Ryland Melchior has 73 resolved cases in Art Unit 1642. The examiner's allowance rate is 63.0%, and the median days to allowance is 1276. The interview lift is 38.5%, indicating that interviews are a very effective strategy in Tech Center 1600. This 38.5% lift is a key data point for the 73 resolved cases in this docket and highlights the examiner's receptiveness to verbal negotiation.
The 63.0% allowance rate indicates a generally positive environment for patent grants, while the 1276-day median pendency shows a standard prosecution timeline. Practitioners should prioritize scheduling an interview, as the 38.5% lift is one of the most significant advantages available in this docket. The examiner's openness to discussion can help resolve issues more quickly than written responses alone. With 73 resolved cases, the data suggests that a proactive approach involving direct communication is the most effective way to navigate the 63.0% baseline allowance rate and reach a successful conclusion.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18592234 | BCMA-TARGETED CAR-T CELL THERAPY FOR MULTIPLE MYELOMA | Non-Final OA | JANSSEN BIOTECH, INC. |
| 18363155 | Multispecific Binding Protein Degrader Platform and Methods of Use | Non-Final OA | Genentech Inc. |
| 18302636 | COMBINATIONAL IMMUNOTHERAPIES USING CAR-M, CAR-NK, CAR-EOS, AND CAR-N CELLS | Non-Final OA | Wisconsin Alumni Research Foundation |
| 18260891 | CROSS-REACTIVE ANTIBODIES RECOGNIZING THE CORONAVIRUS SPIKE S2 DOMAIN | Non-Final OA | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM |
| 17443562 | COMPOSITIONS AND METHODS FOR REDUCING ANTIGEN-SPECIFIC IMMUNOGENICITY | Final Rejection | The Research Foundation for The State University of New York |
| 17616580 | BISPECIFIC BINDING CONSTRUCTS | Final Rejection | AMGEN INC. |
| 18392091 | COMPOSITIONS AND METHODS FOR DETECTING AND TREATING PATHOLOGICAL FIBROBLAST CELLS | Non-Final OA | Duke University |
| 18578850 | COMBINATION DRUG FOR TREATMENT OF GASTRIC CARCINOMA AND/OR ESOPHAGOGASTRIC JUNCTION CANCER | Non-Final OA | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. |
| 18253483 | POLYPEPTIDES TARGETING DR4 AND/OR DR5 AND RELATED COMPOSITIONS AND METHODS | Non-Final OA | The Hospital for Sick Children |
| 18095484 | Engineered T Cells | Non-Final OA | Expression Therapeutics, LLC |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy